Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / P2RY14



This biomarker is also known as:
  • P2Y purinoceptor 14,
  • P2Y(14) receptor,
  • G protein-coupled receptor 105,
  • Q15391,
  • purinergic receptor P2Y, G-protein coupled, 14,
  • UDP-glucose receptor,
  • G protein coupled receptor for UDP-glucose,
  • P2Y14,
  • G-protein coupled receptor 105,
  • GPR105,
  • P2Y14 receptor,
  • KIAA0001,

View in BioMuta


P2RY14, or GPR105, is a G-protein coupled receptor that responds to extracellular purine and pyrimidine nucleotides. P2RY14 is not activated by ATP, ADP, UTP or ATP, but is a receptor for UDP-glucose and other UDP-sugars coupled to G-proteins. P2RY14 is thought to be involved in extending the known immune system functions of P2Y receptors by participating in the regulation of the stem cell compartment, and it may also play a role in neuroimmune function. Two transcript variants encoding the same protein have been identified for this gene. There are two transcript variants for this gene that result in the same protein.


QA State: Curated
Type: Protein
Short Name:
HGNC Name: P2RY14


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Two
QA State: Under Review


No additional ovarian data available.

Performance Comment

P2RY14 (GPR105) was one of 50 tumor vasculature-associated genes with transmembrane or secreted protein products identified through expression profiling of ovarian cancer vascular cells. These 50 tumor vascular markers (TVMs) also had low or no expression in normal tissues. P2RY14 was not in the group of 13 selected for further validation.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

2015 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place January 20–21, 2016 in Bethesda, Maryland.

Announcement 08/26/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held Wednesday-Thursday, January 20-21, 2016, on the NCI campus. More information will be available later this summer.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to /grants/guide/ pa-files/ PAR-15-289.html.